Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain.

The potential utility of adenoviruses for the treatment of chronic neurological disease is controversial due to reports of vector-associated toxicity, inflammation, and transient transgene expression. To focus upon the mechanism by which transgene expression is lost, we injected increasing doses [1 x 10(6) to 1 x 10(9) infectious units (iu)] of a first-generation adenovirus vector expressing beta-galactosidase into the brains of immune-competent adult rats. Transgene expression was evaluated simultaneously with acute neuronal and glial cell cytotoxicity, and acute and chronic inflammation using immunohistochemistry, at 3 and 30 days post-vector administration. Our results show a clear threshold effect of viral dose upon the amount of transgene expression persisting by 30 days after vector administration. Below 10(8) iu, transgene expression remained stable over the 30-day period. Following infection of more than 10(8) iu, the extent of transgene expression at 30 days was inversely correlated with increasing viral dose. The severity of acute inflammation increased proportionally with increasing vector dose from 10(6) to 10(9) infectious units. In contrast, acute vector-mediated cytotoxicity and chronic inflammation were observed only above the threshold level of vector dose. Above 10(8) iu both the extent of the acute toxicity and the severity of the chronic inflammation were inversely correlated with transgene expression at 30 days. Thus, our data suggest that both an acute loss of cells through direct vector-mediated toxicity and the elicitation of chronic inflammation (but not acute inflammation) may account for the decline in transduction persistence at high vector doses.

[1]  P. Lowenstein,et al.  Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  S. Kochanek,et al.  Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Grossman,et al.  Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  G. Wilkinson,et al.  Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK , 2000, Gene Therapy.

[5]  H. Lassmann,et al.  Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials , 1999, Nature Medicine.

[6]  R. Franklin,et al.  Adenoviral vectors for in vivo gene delivery to oligodendrocytes: transgene expression and cytopathic consequences , 1999, Gene Therapy.

[7]  H. Charlton,et al.  A model for long-term transgene expression in spinal cord regeneration studies , 1999, Gene Therapy.

[8]  B. Davidson,et al.  Inflammatory responses and their impact on β-galactosidase transgene expression following adenovirus vector delivery to the primate caudate nucleus , 1999, Gene Therapy.

[9]  K. Brand,et al.  Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection , 1999, Gene Therapy.

[10]  C. Léránth,et al.  Adenovirus-mediated transgene expression in nonhuman primate brain. , 1999, Human gene therapy.

[11]  P. Lowenstein,et al.  Interleukin-1 Mediates a Rapid Inflammatory Response After Injection of Adenoviral Vectors into the Brain , 1999, The Journal of Neuroscience.

[12]  A. Beaudet,et al.  High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. , 1998, Human gene therapy.

[13]  B. Davidson,et al.  Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. , 1998, Human gene therapy.

[14]  J. Verhaagen,et al.  Suppression of inflammation by dexamethasone prolongs adenoviral vector-mediated transgene expression in the facial nucleus of the rat , 1998, Brain Research Bulletin.

[15]  Eugene M. Johnson,et al.  Analysis of Events Leading to Neuronal Death after Infection with E1-Deficient Adenoviral Vectors , 1998, Molecular and Cellular Neuroscience.

[16]  A. Sadikot,et al.  The immunosuppressant FK506 prolongs transgene expression in brain following adenovirus‐mediated gene transfer , 1997, Neuroreport.

[17]  A. Beaudet,et al.  Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. , 1997, Human gene therapy.

[18]  J. Verhaagen,et al.  Adenoviral vector-mediated gene expression in the nervous system of immunocompetent Wistar and T cell-deficient nude rats: preferential survival of transduced astroglial cells in nude rats. , 1997, Human gene therapy.

[19]  D. Hackney,et al.  Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response. , 1997, Human gene therapy.

[20]  G. Wilkinson,et al.  Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. , 1997, The Journal of general virology.

[21]  B. Trapnell,et al.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy , 1996, Journal of virology.

[22]  L. D. Dion,et al.  Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. , 1996, Journal of virological methods.

[23]  M. Wood,et al.  Adenovirus gene transfer causes inflammation in the brain , 1995, Neuroscience.

[24]  G. Wilkinson,et al.  Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. , 1992, Nucleic acids research.